FDA Accepts Anesiva's sNDA for Pain Drug

                   
redorbit.com     May 22, 2008            

Posted on: Thursday, 22 May 2008, 09:01 CDT Anesiva has announced that the FDA has accepted the company's electronic supplemental new drug application filing to expand the indication for Zingo to treat pain associated with peripheral IV insertions and blood draws in adults. The sNDA submission is... [read full story]                

Full Coverage
                   

FDA Accepts Anesiva, Inc.'s Zingo(TM) Supplemental New Drug Application to Reduce Pain Associated...

biospace.com     May 21, 2008          

SOUTH SAN FRANCISCO, Calif., May 21 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV - News) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's electronic supplemental New Drug Application (sNDA) filing to expand the indication for Zingo to treat pain...                

comments

                   

FDA Accepts Zingo(TM) Supplemental New Drug Application to Reduce Pain Associated With Peripheral...

yahoo.com     May 21, 2008          

Anesiva, Inc. today announced that the U.S. Food and Drug Administration has accepted the company's electronic supplemental New Drug Application filing to expand the indication for Zingo to treat pain associated with peripheral IV insertions and blood draws in adults.                

comments

                   

FDA Accepts Zingo Supplemental Drug For Pain Treatment

emaxhealth.com     May 23, 2008          

FDA has accepted Anesiva's electronic supplemental New Drug Application (sNDA) filing to expand the indication for Zingo to treat pain associated with peripheral IV insertions and blood draws in adults. Zingo (lidocaine hydrochloride monohydrate) powder intradermal injection system is already...                

comments